Materna Medical Presents a Sub-Analysis Comparing Outcomes on a Spectrum of Menopausal Women, showing significant improvements at three months
Data presented at the Menopause Society Annual Meeting compared Milli expanding vaginal dilator therapy results in women over and under age 50
October 22, 2025 [Mountain View, Calif.]—Materna Medical announced today that an interim menopause-focused sub-analysis from the Prospective On Market Patient-reported Outcomes for Milli (POMPOM) clinical study will be presented at The Menopause Society 2025 Annual Meeting.
The abstract, titled “An Interim Menopause Sub-Analysis of the POMPOM Study Evaluating the Efficacy of the Milli Expanding Dilator as a Treatment for Achieving Intercourse,” highlights promising results in women aged 50 and older using the Milli vaginal dilator, an FDA-cleared device designed to treat vaginismus and dyspareunia.
When asked to describe any impact that Milli has had on their sex life, one POMPOM participant reported, “My sex life is much better, and I really AM NOT too old! :).”
